RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine
Summary
CEO Prahlad Singh pointed to solid organic growth in diagnostics and software, which helped offset weaker demand from U.S. academic customers affecting the life sciences instruments business. Looking ahead, management’s full-year outlook reflects continued caution around U.S. academic funding, ongoing mitigation of tariff-related headwinds, and confidence in the company’s ability to adapt quickly. Singh also emphasized the role of new product launches and commercial partnerships in diagnostics, as well as robust growth in the Signals software business, as key contributors to Revvity’s projected performance for the remainder of 2025. Revvity’s leadership attributed first quarter performance to the interplay of stable diagnostics demand, robust software expansion, and targeted operational adjustments in response to industry-specific challenges. Our Favorite Stocks Right Now Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.